EDX Medical completed its reversal into TECC Capital on 14 November. The share price returned from suspension and increased by 64.1% to 5.25p, but it is still below the placing price of 6p.
Management believes that the sector will consolidate and EDX Medical should be at the forefront of this. Partnerships will help to broaden the range of diagnostics offered by EDX Medical.
It is still early days for the business, and it is yet to generate revenues. The valuation appears full unless an i...
You are unauthorized to view this page.